Summary
This Form 8-K filing by CVS Health Corporation (CVS) on March 8, 2018, primarily addresses a supplemental disclosure related to the previously announced merger with Aetna Inc. A shareholder class action lawsuit was filed by a CVS Health stockholder challenging the merger and alleging breaches of fiduciary duty by the CVS Health Board and insufficient disclosure in the preliminary proxy statement. CVS Health, while believing the claims are without merit, has voluntarily supplemented its disclosures to avoid potential delays or adverse effects on the transaction. This supplemental information aims to address the plaintiff's concerns, leading to the plaintiff's agreement to dismiss the lawsuit. The company emphasizes that this disclosure does not constitute an admission of liability or wrongdoing.
Key Highlights
- 1CVS Health is filing supplemental disclosures to its joint proxy statement/prospectus regarding the Aetna merger.
- 2A shareholder class action lawsuit ('Gawrych v. Merlo et al.') was filed against CVS Health directors and the company.
- 3The lawsuit alleges breaches of fiduciary duty and inadequate disclosure concerning the Aetna merger.
- 4CVS Health believes the lawsuit's claims are without merit but is providing supplemental disclosures to mitigate transaction risks.
- 5Supplemental disclosures clarify the rationale for selecting Aetna over other potential transactions and provide details on the selection of financial advisors (Barclays and Goldman Sachs).
- 6Information regarding the net long position of Barclays in Aetna shares and Goldman Sachs' lack of direct equity investment in Aetna as of the opinion date is also disclosed.
- 7The plaintiff has agreed to dismiss the lawsuit in light of the supplemental disclosures, with CVS Health denying any legal necessity for these additional disclosures.